^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoCompass™ Target

    Company:
    Burning Rock Biotech
    Type:
    CE Marked
    Related tests:
    OncoCompass™ Target is ctDNA liquid biopsy-based test for NSCLC which is upgraded to a pan-cancer test for all solid tumors. This test analyzes 168 genes that are related to the development of NSCLC and solid tumors, including all genes that have a targeted therapy that is FDA- or NMPA-approved or NCCN-recommended. It provides information with optimal clinical value for cancer patients, especially advanced-stage cancer patients who do not have accessible tissue, for various solid tumors across treatment stages, from baseline profiling, dynamic monitoring to MRD detection.
    Cancer:
    Non Small Cell Lung Cancer
    Gene:
    ALK (Anaplastic lymphoma kinase), EGFR (Epidermal growth factor receptor), PD-L1 (Programmed death ligand 1), TMB (Tumor Mutational Burden)
    Drug:
    Tagrisso (osimertinib)
    Method:
    Next-Generation Sequencing (NGS)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    05/07/22
    ST
    -
    CE